Company Profile
Pliant Therapeutics Stock Price, News & Catalysts
- Ticker:
- PLRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.10 USD (+2.80%)
Close
Last updated: August 17, 2026
71.8M USD
Market cap
Why the stock is moving
The latest monitored company update is āPliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors.ā The corresponding closing-price reaction is not yet available.
Company overview
Integrin-Targeted Drug Discovery
Pliant Therapeutics is a clinical-stage biotechnology company developing therapies that modulate integrin-mediated biological pathways. Its current development focus centers on oncology and targeted drug delivery.
PLN-101095
PLN-101095 is an oral small molecule that selectively inhibits the Ī±vĪ²8 and Ī±vĪ²1 integrins. It is designed to block TGF-Ī² activation in the tumor microenvironment and overcome resistance to immune checkpoint inhibitors.
FORTIFY Expansion Study
The Phase 1b FORTIFY study evaluates PLN-101095 with pembrolizumab in checkpoint-inhibitor-refractory solid tumors. Expansion cohorts include non-small cell lung cancer, clear-cell renal-cell carcinoma, and tumors with high tumor mutational burden.
Integrin-Targeted Delivery Platform
Pliant is also using integrin receptor-binding molecules to deliver payloads to specific tissues. Preclinical programs are evaluating siRNA delivery to skeletal muscle cells, adipocytes, and renal cells.
Future catalysts
- Interim data from the Phase 1b FORTIFY expansion study in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pliant Therapeutics (PLRX)?
Pliant Therapeutics (PLRX) most recently closed at 1.10 USD, a +2.80% move versus the previous session.
What is the market cap of Pliant Therapeutics (PLRX)?
Pliant Therapeutics currently has a market capitalization of 71.8M USD on BioPharmSignal.
What does Pliant Therapeutics do?
Integrin-Targeted Drug Discovery Pliant Therapeutics is a clinical-stage biotechnology company developing therapies that modulate integrin-mediated biological pathways. Its current development focus centers on oncology and targeted drug delivery. PLN-101095 PLN-101095 is an oral small molecule that selectively inhibits the Ī±vĪ²8 and Ī±vĪ²1 integrins. It is...
On which exchange is PLRX stock listed?
Pliant Therapeutics (PLRX) is associated with NASDAQ, United States, Biopharma.
What is PLN-101095?
PLN-101095 PLN-101095 is an oral small molecule that selectively inhibits the Ī±vĪ²8 and Ī±vĪ²1 integrins.
Which conditions is Pliant Therapeutics targeting with PLN-101095?
Pliant Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Pliant Therapeutics describe recent progress with PLN-101095?
Interim data from the Phase 1b FORTIFY expansion study in 2027.
What is pembrolizumab?
FORTIFY Expansion Study The Phase 1b FORTIFY study evaluates PLN-101095 with pembrolizumab in checkpoint-inhibitor-refractory solid tumors.